By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Essen BioScience today said that it will provide ion channel screening services for Swiss drug firm Nycomed.

Ann Arbor, Mich.-based Essen said that the firms will collaborate on screening, optimizing, and developing modulators of voltage-gate ion channels for potential use as pain therapeutics. Essen said that it will contribute its expertise in ion channel drug discovery, planar array electrophysiology, and in vitro profiling.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.